These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8371575)

  • 1. MK 886, an antagonist of leukotriene generation, inhibits DNA synthesis in a subset of acute myeloid leukaemia cells.
    Khan MA; Hoffbrand AV; Mehta A; Wright F; Tahami F; Wickremasinghe RG
    Leuk Res; 1993 Sep; 17(9):759-62. PubMed ID: 8371575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that endogenous generation of leukotrienes does not regulate proliferation of malignant hemopoietic cell lines.
    Ayyub Khan M; Tateson JE; Hoffbrand AV; Wickremasinghe RG
    Leuk Res; 1993 Mar; 17(3):241-5. PubMed ID: 8450672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-886, a leukotriene biosynthesis inhibitor, induces antiproliferative effects and apoptosis in HL-60 cells.
    Dittmann KH; Mayer C; Rodemann HP; Petrides PE; Denzlinger C
    Leuk Res; 1998 Jan; 22(1):49-53. PubMed ID: 9585079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside incorporation into DNA and RNA in acute leukaemia: differences between the various leukaemia sub-types.
    Piga A; Sylwestrowicz T; Ganeshaguru K; Breatnach F; Amos R; Prentice HG; Hoffbrand AV
    Br J Haematol; 1982 Oct; 52(2):195-204. PubMed ID: 6957240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospholipase A2 inhibitors and leukotriene synthesis inhibitors block TNF-induced NF-kappaB activation.
    van Puijenbroek AA; Wissink S; van der Saag PT; Peppelenbosch MP
    Cytokine; 1999 Feb; 11(2):104-10. PubMed ID: 10089130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA synthesis in thymic-acute lymphoblastic leukaemia.
    Piga A; Ganeshaguru K; Lee N; Breatnach F; Prentice HG; Hoffbrand AV
    Br J Haematol; 1981 Aug; 48(4):585-94. PubMed ID: 6944098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of MK-886 on arachidonic acid metabolism in human phagocytes.
    Ménard L; Pilote S; Naccache PH; Laviolette M; Borgeat P
    Br J Pharmacol; 1990 May; 100(1):15-20. PubMed ID: 2164857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.
    Prasit P; Belley M; Blouin M; Brideau C; Chan C; Charleson S; Evans JF; Frenette R; Gauthier JY; Guay J
    J Lipid Mediat; 1993; 6(1-3):239-44. PubMed ID: 8357985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.
    Evans JF; Lévillé C; Mancini JA; Prasit P; Thérien M; Zamboni R; Gauthier JY; Fortin R; Charleson P; MacIntyre DE
    Mol Pharmacol; 1991 Jul; 40(1):22-7. PubMed ID: 1857337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leucine incorporation into leukaemic blast cells.
    Lange Wantzin G
    Biomedicine; 1979 Oct; 31(6):158-63. PubMed ID: 294296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel leukotriene--based anti-asthma drugs: MK-886 and MK-571.
    Young RN
    Agents Actions Suppl; 1991; 34():179-87. PubMed ID: 1793062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of interleukin-1, tumor necrosis factor-alpha, and interferon-alpha on the blast cells of acute myeloblastic leukemia.
    Carter A; Silvian-Draxler I; Tatarsky I
    Am J Hematol; 1992 Aug; 40(4):245-51. PubMed ID: 1503080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
    Reuter C; Auf der Landwehr U; Schleyer E; Zühlsdorf M; Ameling C; Rolf C; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1994 Feb; 8(2):217-25. PubMed ID: 8309245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
    Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA replication of human acute leukemia cells cultured in vitro.
    Ribas-Mundo M
    Acta Haematol; 1974; 52(4):201-6. PubMed ID: 4217524
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of lipoxygenase and glutathione pathway inhibitors on leukemic cell line growth.
    Miller AM; Cullen MK; Kobb SM; Weiner RS
    J Lab Clin Med; 1989 Mar; 113(3):355-61. PubMed ID: 2494278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in sensitivity of DNA synthesis to ara-C in acute myeloid leukaemia.
    Harris AL; Grahame-Smith DG
    Br J Haematol; 1980 Jul; 45(3):371-9. PubMed ID: 6932952
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
    Tagari P; Brideau C; Chan C; Frenette R; Black C; Ford-Hutchinson A
    Agents Actions; 1993 Sep; 40(1-2):62-71. PubMed ID: 8147271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.
    Gillard J; Ford-Hutchinson AW; Chan C; Charleson S; Denis D; Foster A; Fortin R; Leger S; McFarlane CS; Morton H
    Can J Physiol Pharmacol; 1989 May; 67(5):456-64. PubMed ID: 2548691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.